An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MK-3102 in Patients With Impaired Renal Function.
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Omarigliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 24 Apr 2012 Actual patients number is 49 as reported by ClinicalTrials.gov.
- 10 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.